Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development.

Chassagnole C, Jackson RC, Hussain N, Bashir L, Derow C, Savin J, Fell DA.

Biosystems. 2006 Feb-Mar;83(2-3):91-7. Epub 2005 Oct 19.

PMID:
16236428
2.
3.

Computational experiments reveal the efficacy of targeting CDK2 and CKIs for significantly lowering cellular senescence bar for potential cancer treatment.

Ling H, Samarasinghe S, Kulasiri D.

Biosystems. 2013 Feb;111(2):71-82. doi: 10.1016/j.biosystems.2012.12.001. Epub 2012 Dec 17.

PMID:
23254306
4.
5.

Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.

Legraverend M, Ludwig O, Bisagni E, Leclerc S, Meijer L, Giocanti N, Sadri R, Favaudon V.

Bioorg Med Chem. 1999 Jul;7(7):1281-93.

PMID:
10465404
6.

Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.

Baselga J, Mita AC, Schöffski P, Dumez H, Rojo F, Tabernero J, DiLea C, Mietlowski W, Low C, Huang J, Dugan M, Parker K, Walk E, van Oosterom A, Martinelli E, Takimoto CH.

Clin Cancer Res. 2012 Nov 15;18(22):6364-72. doi: 10.1158/1078-0432.CCR-12-1499. Epub 2012 Sep 26.

7.

Cyclin-dependent kinase modulators and cancer therapy.

Gallorini M, Cataldi A, di Giacomo V.

BioDrugs. 2012 Dec 1;26(6):377-91. doi: 10.2165/11634060-000000000-00000. Review.

PMID:
22928661
8.

Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.

Blachly JS, Byrd JC, Grever M.

Semin Oncol. 2016 Apr;43(2):265-73. doi: 10.1053/j.seminoncol.2016.02.003. Epub 2016 Feb 8. Review.

PMID:
27040705
9.

An agent-based stochastic tumor model for predicting mitotic arrest drug response.

Fox BM, Moffitt RA, Wang MD.

Conf Proc IEEE Eng Med Biol Soc. 2008;2008:5458-61. doi: 10.1109/IEMBS.2008.4650449.

PMID:
19163952
10.

Accounting for quiescent cells in tumour growth and cancer treatment.

Florian JA Jr, Eiseman JL, Parker RS.

Syst Biol (Stevenage). 2005 Dec;152(4):185-92.

PMID:
16986259
11.

Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.

Senderowicz AM.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S61-73. Epub 2003 Jun 18. Review.

PMID:
12819936
12.

The effects of a telomere destabilizing agent on cancer cell-cycle dynamics--integrated modelling and experiments.

Hirt BV, Wattis JA, Preston SP, Laughton CA.

J Theor Biol. 2012 Feb 21;295:9-22. doi: 10.1016/j.jtbi.2011.10.038. Epub 2011 Nov 18.

13.

Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis.

Schättler H, Ledzewicz U, Cardwell B.

Math Biosci Eng. 2011 Apr;8(2):355-69. doi: 10.3934/mbe.2011.8.355.

PMID:
21631134
14.

Targeting breast cancer with CDK inhibitors.

Mayer EL.

Curr Oncol Rep. 2015;17(5):443. doi: 10.1007/s11912-015-0443-3. Review.

PMID:
25716100
15.
16.

ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.

Abate AA, Pentimalli F, Esposito L, Giordano A.

Expert Opin Investig Drugs. 2013 Jul;22(7):895-906. doi: 10.1517/13543784.2013.798641. Epub 2013 Jun 4. Review.

PMID:
23735075
17.

Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.

Senderowicz AM.

Cancer Chemother Biol Response Modif. 2001;19:165-88. Review.

PMID:
11686013
18.

VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.

Shao Z, Bao Q, Jiang F, Qian H, Fang Q, Hu X.

PLoS One. 2015 Jul 23;10(7):e0132655. doi: 10.1371/journal.pone.0132655. eCollection 2015.

19.

Progress in the evaluation of CDK inhibitors as anti-tumor agents.

McInnes C.

Drug Discov Today. 2008 Oct;13(19-20):875-81. doi: 10.1016/j.drudis.2008.06.012. Epub 2008 Aug 3. Review.

PMID:
18639646
20.

Predictive relevance for clinical outcome of in vitro sensitivity evaluated through antimetabolic assay.

Silvestrini R, Sanfilippo O, Daidone MG, Zaffaroni N.

Recent Results Cancer Res. 1984;94:140-50. No abstract available.

PMID:
6494575

Supplemental Content

Support Center